David S Hong, Kathleen N Moore, Manish R Patel, Stefan C Grant, Howard A Burris, William N William, Suzanne Jones, Funda Meric-Bernstam, Jeffrey Infante, Lisa Golden, Wei Zhang, Ricardo Martinez, Sameera R Wijayawardana, Richard P Beckmann, Aimee Bence Lin, Cathy Eng, Johanna C Bendell
PURPOSE: Prexasertib, a checkpoint kinase 1 inhibitor, demonstrated single-agent activity in patients with advanced squamous cell carcinoma (SCC) in the dose-escalation portion of a Phase I study (NCT01115790). Monotherapy prexasertib was further evaluated in patients with advanced SCC. EXPERIMENTAL DESIGN: Patients were given prexasertib 105 mg/m2 as a 1-hour infusion on day 1 of a 14-day cycle. Expansion cohorts were defined by tumor and treatment line. Safety, tolerability, efficacy, and exploratory biomarkers were analyzed...
April 11, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research